The pattern of KRAS mutations in non-small cell lung cancer (NSCLC): A retrospective study from south-eastern Georgia.

被引：0
|
作者：
Matosz, Sabrina
Elzaidy, Mostafa
Karim, Nagla Fawzy Abdel
机构：
[1] Augusta Univ, Med Coll Georgia, Augusta, GA USA
[2] Maadi Mil Hosp, Cairo, Egypt
[3] Augusta Univ, Med Ctr, Augusta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15110
引用
收藏
页数：1
相关论文
共 50 条
  • [11] EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study
    Sema Bircan
    Huseyin Baloglu
    Zafer Kucukodaci
    Ahmet Bircan
    Medical Oncology, 2014, 31
  • [12] KRAS Mutations as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer
    Martin, Petra
    Leighl, Natasha B.
    Tsao, Ming-Sound
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (05) : 530 - 542
  • [13] KRAS codon 12 mutations in Australian non-small cell lung cancer
    Fong, KM
    Zimmerman, PV
    Smith, PJ
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1998, 28 (02): : 184 - 189
  • [14] Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
    Becker, Caroline
    Carcereny Costa, Enric
    Andreo Garcia, Felipe
    Castella, Eva
    Lletjos Sanuy, Mariona
    Moran, Teresa
    Mijangos Basterra, Erika
    Sanz Santos, Jose
    Centeno Clemente, Carmen
    Ruiz Manzano, Juan
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [15] KRAS molecular profiling in non-squamous non-small cell lung cancer (NSCLC).
    Karim, Nagla Abdel
    Starnes, Sandra
    Morris, John
    Pathrose, Peter
    Perry, Ashley
    Fathallah, Hassana
    CLINICAL CANCER RESEARCH, 2014, 20
  • [16] KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy
    Danenberg, K. D.
    Grimminger, P. P.
    Mack, P. C.
    Danenberg, P. V.
    Cooc, J.
    Stephens, C.
    Reddy, S. K.
    Li, T.
    Gandara, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [17] Efficacy of current immunotherapies in patients (pt) with metastatic non-small cell lung cancer (NSCLC) harboring KRAS mutations
    Rincon, L. Notario
    Pous, A.
    Paradis, A. Lopez
    Notario, A.
    Salamero, M. Cucurull
    Gonzalez, A. Hernandez
    Vinolas, M. Domenech
    Costa, E. Carcereny
    Bueno, M. T. Moran
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Morgui, M. Saigi
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1066 - S1067
  • [18] Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy
    Mellema, Wouter W.
    Dingemans, Anne-Marie C.
    Smit, Egbert F.
    Derks, Jules
    Heideman, Danielle A. M.
    van Suylen, Robertjan
    Thunnissen, Frederik B.
    CLINICAL CANCER RESEARCH, 2012, 18 (03)
  • [19] PREDICTIVE VALUE OF KRAS AND BRAF MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CHEMOTHERAPY
    Dingemans, Anne-Marie
    Smit, Egbert F.
    Heideman, Danielle
    Mellema, Wouter
    Derks, Jules
    Van, Robertjan Suylen
    Thunnissen, Erik
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1044 - S1044
  • [20] A RANDOMIZED DISCONTINUATION PHASE II TRIAL OF RIDAFOROLIMUS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH KRAS MUTATIONS
    Riely, Gregory J.
    Brahmer, Julie
    Planchard, David
    Crino, Lucio
    Doebele, Robert C.
    Maz Lopez, Luis
    Gettinger, Scott N.
    Schumann, Christian
    Guan, Shanghong
    Atkins, B.
    Ebbinghaus, S.
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S608 - S609
12345